TISLELIZUMAB

This study tests whether adding a single, low dose of radiation to the small intestine can make a standard immunotherapy-plus-chemotherapy regimen work better for people with esophageal cancer that cannot be easily removed by surgery. About 43 adults with borderline resectable or…

This phase 2 trial tests a combination of three drugs (tislelizumab, anlotinib, and nab-paclitaxel) given before surgery to people with stage III non-small cell lung cancer. The goal is to see if this approach can eliminate or greatly reduce the tumor before it is removed. The st…

This study tests whether two drugs, fruquintinib and tislelizumab, can control leftover cancer cells in people with colorectal cancer who have completed chemotherapy but still show signs of minimal residual disease (MRD) on a blood test. About 20 adults with stable disease will r…

This phase 2 trial is testing whether adding a probiotic called Probio-M9 to standard chemoradiation and an immunotherapy drug (tislelizumab) can improve outcomes for people with locally advanced rectal cancer. About 50 participants will be randomly assigned to receive either the…

This phase II trial tests whether a combination of tislelizumab (an immunotherapy) and nab-paclitaxel (a chemotherapy drug) can treat renal pelvic cancer while allowing patients to keep their kidney. About 35 adults with early-stage cancer will receive the drugs, and if the tumor…

This study is for people with advanced non-small cell lung cancer (stage IIIB/C-IV) who cannot tolerate standard chemoradiation. It tests a treatment plan of platinum-based chemotherapy, followed by a special type of radiation and the immunotherapy drug Tislelizumab. The goal is …